CLINICAL-PATHOLOGICAL SIGNIFICANCE OF THE BIOMARKERS RRM1, MGMT, TUBB3, AND PTEN IN SEVERAL HISTOLOGICAL SUBTYPES OF SOFT TISSUE SARCOMAS (MATHEMATICAL MODELING OF SURVIVAL BASED ON A SYNTHETIC COHORT)

Authors:

Abstract:

Soft tissue sarcomas are rare but highly heterogeneous mesenchymal tumors. In this study, the clinical-pathological significance of the biomarkers RRM1, MGMT, TUBB3, and PTEN in patients with soft tissue sarcomas was evaluated using a model-based statistical approach. A synthetic cohort of 250 patients was created, and overall survival and progression-free survival were analyzed using Kaplan-Meier and Cox proportional hazard models. According to the results obtained, the hazard ratio for overall survival associated with PTEN loss was approximately 1.9, for progression-free survival associated with high TUBB3 expression 1.7, and for low RRM1 expression in gemcitabine-treated patients 0.53. Thus, biomarkers such as RRM1, TUBB3, and PTEN have considerable potential for planning individualized treatment strategies in patients with soft tissue sarcoma; MGMT methylation may serve as a predictive marker in selected cases.

Keywords:

soft tissue sarcoma RRM1 TUBB3 PTEN MGMT Kaplan–Meier Cox model

References:

1. Cancer Genome Atlas Research Network. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell. 2017 Nov 2;171(4):950-965.e28. doi: 10.1016/j.cell.2017.10.014.
2. Jagosky MH, Anderson CJ, Symanowski JT, Steuerwald NM, Farhangfar CJ, Baldrige EA, et al. Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma. Cancer Med. 2023 Mar;12(6):7029-7038. doi: 10.1002/cam4.5502.
3. Kirilin EM, Fetisov TI, Moiseeva NI, Lesovaya EA, Laletina LA, Makhmudova LF, et al. Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin. Cancers (Basel). 2022 Apr 1;14(7):1796. doi: 10.3390/cancers14071796.
4. Lopez G, Boggio F, Ferrero S, Fusco N, Del Gobbo A. Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma. Int J Mol Sci. 2018 Oct 3;19(10):3014. doi: 10.3390/ijms19103014.
5. Pan M, Zhou M, Xie L, Bui N, Ganjoo K. Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers. J Hematol Oncol. 2024 Dec 18;17(1):124. doi: 10.1186/s13045-024-01650-6.
6. Pillozzi S, Bernini A, Palchetti I, Crociani O, Antonuzzo L, Campanacci D, et al. Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level. Cancers (Basel). 2021 Jun 18;13(12):3044. doi: 10.3390/cancers13123044.
7. Spałek MJ, Kozak K, Czarnecka AM, Bartnik E, Borkowska A, Rutkowski P. Neoadjuvant Treatment Options in Soft Tissue Sarcomas. Cancers (Basel). 2020 Jul 26;12(8):2061. doi: 10.3390/cancers12082061.
8. Stefano S, Giovanni S. The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma. Cancers (Basel). 2019 Aug 14;11(8):1169. doi: 10.3390/cancers11081169.
9. Tóth C, Sükösd F, Valicsek E, Herpel E, Schirmacher P, Renner M, et al. Expression of ERCC1, RRM1, TUBB3 in correlation with apoptosis repressor ARC, DNA mismatch repair proteins and p53 in liver metastasis of colorectal cancer. Int J Mol Med. 2017 Nov;40(5):1457-1465. doi: 10.3892/ijmm.2017.3136.
10. Vargas AC, Gray LA, White CL, Maclean FM, Grimison P, Ardakani NM, et al. Genome wide methylation profiling of selected matched soft tissue sarcomas identifies methylation changes in metastatic and recurrent disease. Sci Rep. 2021 Jan 12;11(1):667. doi: 10.1038/s41598-020-79648-6.
11. Xu L, Xie X, Shi X, Zhang P, Liu A, Wang J, Zhang B. Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma. Oncol Lett. 2021 May;21(5):353. doi: 10.3892/ol.2021.12614.

Publication:

«World of Medicine and Biology» Vol. 22 No. 1 (2026) , с. 61-66
УДК 616-006.5:616-091:577.21

DOI:

https://doi.org/10.26724/2079-8334-2026-1-95-61-66